Emmaus Life SciencesEMMA -16.67% Days Payable is 2,673.41 as of Mar. 2026, which is 159% above its 10-year median of 1,030.52. The stock has 6 warning signs investors should review. Among 707 Biotechnology companies, Emmaus Life Sciences ranks better than 90.52% on this metric.
The historical rank and industry rank for Emmaus Life Sciences's Days Payable or its related term are showing as below:
EMMA'
s Days Payable Range Over the Past 10 Years
Min: 238.93 Med: 1030.52 Max: 46683.5
Current: 2099.94
During the past 13 years, Emmaus Life Sciences's highest Days Payable was 46683.50. The lowest was 238.93. And the median was 1030.52.
EMMA's Days Payable is ranked better than 90.52% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs EMMA: 2099.94
Emmaus Life Sciences's Days Payable
increased
from Mar. 2025 (1,328.19) to Mar. 2026 (2,673.41).
It may suggest that Emmaus Life Sciencesdelayed paying its suppliers.
Emmaus Life Sciences Days Payable Related Terms
Emmaus Life Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Emmaus Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Emmaus Life Sciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a Days Payable of 2,673.41 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Emmaus Life Sciences and its competitors. This is 159% above median its historical median of 1,030.52. Over the past decade, Emmaus Life Sciences' Days Payable has ranged from 238.93 to 46,683.50. According to the industry distribution chart, Emmaus Life Sciences ranks #67 out of 707 companies in the Biotechnology industry, placing it in the top 9.5%.
Is Emmaus Life Sciences' Days Payable too high?
Emmaus Life Sciences' current Days Payable of 2,673.41 is 159% above median its 10-year median of 1,030.52. Over the past 10 years, this metric has ranged from a low of 238.93 to a high of 46,683.50. The Biotechnology industry median Days Payable is 113.76. Emmaus Life Sciences' value of 2,673.41 is 2250% above this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #67 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Emmaus Life Sciences' Days Payable compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #67 out of 707 companies for Days Payable. This places Emmaus Life Sciences in the top 10% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Emmaus Life Sciences' value of 2,673.41 is 2250% above this benchmark. Historically, Emmaus Life Sciences' own Days Payable has ranged from 238.93 to 46,683.50 over the past decade. While the company's 10-year median is 1,030.52 vs. the industry median of 113.76, Emmaus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Days Payable of 2,673.41 is 2250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Days Payable is 2,673.41, which is 159% above median its own 10-year median of 1,030.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Days Payable is 2,673.41, which is 159% above median its 10-year median of 1,030.52 and 2250% above the Biotechnology industry median of 113.76. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Days Payable is 2,673.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 